mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2018-9-3-44-49mvjr-675Research ArticleОБЗОРЫREVIEWБезопасность и эффективность терапии генно-инженерно-биологическими препаратами ревматоидного артритаSafety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritishttps://orcid.org/0000-0002-5129-0402СтрельцовЕ. А.Strel’tsovE. A.

Стрельцов Евгений Александрович, врач-интерн, внутренние болезни

Evgeniy A. Strel’tsov, internal illnesses, intern doctor

lidigi@mail.ruКарагандинский государственный медицинский университет, КарагандаКазахстанKaraganda State Medical University, KaragandaKazakhstan201801102018934449Copyright © Стрельцов Е.А., 20182018Стрельцов Е.А.Strel’tsov E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/675

В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии генно-инженерно-биологическими препаратами при ревматоидном артрите. Подробно освещены результаты рандомизированных исследований последних лет. Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и др.

In this review of the literature, questions of the efficacy and safety of therapy with genetically engineered biological preparations for rheumatoid arthritis are discussed. The results of randomized trials of recent years are described in detail. Systematic literature search was conducted on the databases Scopus, Web of Science, MedLine, elibrary and others.

генно-инженерные-биологические препаратыревматоидный артриттоцилизумабритуксимабинфликсимабэтанерцептgenetically engineered biological preparationsrheumatoid arthritistocilizumabrituximabinfliximabetanerceptReferencesSmolen J.S, Aletaha D., McInnes I.B. Rheumatoid arthritis. // Lancet. – 2016. – V.388(10055). – P.2023-2038. doi: 10.1016/S0140-6736(16)30173-8Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8Vriezekolk J.E., van Lankveld W.G., Geenen R., van den Ende C.H. Longitudinal association between coping and psychological distress in rheumatoid arthritis: a systematic review. // Ann Rheum Dis. – 2011. – V.70(7). – P.1243-50. doi: 10.1136/ard.2010.143271Vriezekolk JE, van Lankveld WG, Geenen R, van den Ende CH. Longitudinal association between coping and psychological distress in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2011;70(7):1243-50. doi: 10.1136/ard.2010.143271Rodríguez L.A., Tolosa L.B., Ruigomez A., Johansson S., Wallander M.A. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. // Scand J Rheumatol.– 2009. – V. 38(3). – P. 173-7. doi: 10.1080/03009740802448825Rodríguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol. 2009;38(3):173-7. doi: 10.1080/03009740802448825Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. // Arthritis Res Ther. – 2009. – V. 11(3). – P. 229. doi: 10.1186/ar2669Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669Scott D.L, Wolfe F., Huizinga T.W. Rheumatoid arthritis. // Lancet. – 2010. – V. 376(9746). – P. 1094-108. doi: 10.1016/S0140-6736(10)60826-4Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-108. doi: 10.1016/S0140-6736(10)60826-4Huang C.M., Chen H.H., Chen D.C., Huang Y.C., Liu S.P., Lin Y.J. Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR protein. // PLoS One. – 2017. – V. 12(7). – P. e 0180604. doi: 10.1371/journal.pone.0180604Huang CM, Chen HH, Chen DC, Huang YC, Liu SP, Lin YJ et all. Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR protein. PLoS One. 2017;12(7):e0180604. doi: 10.1371/journal.pone.0180604Lai C.H., Lai M.S., Lai K.L., Chen H.H., Chiu Y.M. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. // Clin Exp Rheumatol. – 2012. – V. 30(3). – P. 358–363.Lai CH, Lai MS, Lai KL, Chen HH, Chiu YM. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. Clin Exp Rheumatol.2012;30(3):358–363Kuo C.F., Luo S.F., See L.C., Chou I.J., Chang H.C., Yu K.H. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. // Rheumatol Int. – 2013. - V. 33(2). – P. 355-60. doi: 10.1007/s00296-012-2411-7Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int. 2013;33(2):355-60. doi: 10.1007/s00296-012-2411-7Zhu H., Xia W., Mo X.B., Lin X., Qiu Y.H., Yi N.J. GeneBased Genome-Wide Association Analysis in European and Asian Populations Identified Novel Genes for Rheumatoid Arthritis. // PLoS One. – 2016. – V. 11(11). – P. e 0167212. doi: 10.1371/journal.pone.0167212Zhu H, Xia W, Mo XB, Lin X, Qiu YH, Yi NJ et all. GeneBased Genome-Wide Association Analysis in European and Asian Populations Identified Novel Genes for Rheumatoid Arthritis. PLoS One. 2016;11(11):e0167212. doi: 10.1371/journal.pone.0167212McGettrick H.M., Butler L.M., Buckley C.D., Rainger G.E., Nash G.B. Tissue stroma as a regulator of leukocyte recruitment in inflammation. // J Leukoc Biol. – 2012. - V. 91(3). – P. 385-400. doi: 10.1189/jlb.0911458McGettrick HM, Butler LM, Buckley CD, Rainger GE, Nash GB. Tissue stroma as a regulator of leukocyte recruitment in inflammation. J Leukoc Biol. 2012;91(3):385-400. doi: 10.1189/jlb.0911458Filer A., Ward L.S.C., Kemble S., Davies C.S., Munir H., Rogers R. Identification of a transitional fibroblast function in very early rheumatoid arthritis. // Ann Rheum Dis.– 2017. - V. 76(12). – P. 2105-2112. doi: 10.1136/annrheumdis-2017-211286Filer A, Ward LSC, Kemble S, Davies CS, Munir H, Rogers R et all. Identification of a transitional fibroblast function in very early rheumatoid arthritis. Ann Rheum Dis.2017;76(12):2105-2112. doi: 10.1136/annrheumdis-2017-211286Guo Z.Y., Zhang J.X., Wu M., Mei Y.F., Lin X.J., Bu C. Metaanalysis of the association between PADI4 -92C/G polymorphism and rheumatoid arthritis in the Chinese population. // Braz J Med Biol Res. – 2017. – V. 50(10). – P. e 6115. doi: 10.1590/1414-431X20176115Guo ZY, Zhang JX, Wu M, Mei YF, Lin XJ, Bu C et all. Metaanalysis of the association between PADI4 -92C/G polymorphism and rheumatoid arthritis in the Chinese population. Braz J Med Biol Res. 2017;50(10):e6115. doi: 10.1590/1414-431X20176115Luukkonen J., Pascual L.M., Patlaka C., Lang P., Turunen S., Halleen J. Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritissynovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio. // PLoS One. – 2017. – V. 12(8). – P. e 0182904. doi: 10.1371/journal.pone.0182904Luukkonen J, Pascual LM, Patlaka C, Lang P, Turunen S, Halleen J et all. Increased amount of phosphorylated proinfl ammatory osteopontin in rheumatoid arthritissynovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio. PLoS One. 2017;12(8):e0182904. doi: 10.1371/journal.pone.0182904Loupasakis K., Kuo D., Sokhi U.K., Sohn C., Syracuse B., Giannopoulou E.G. Tumor Necrosis Factor dynamically regulates the mRNA stabilome in rheumatoid arthritisfi broblastlike synoviocytes. // PLoS One. – 2017. V. 12(7). – P.e0179762. doi: 10.1371/journal.pone.0179762Loupasakis K, Kuo D, Sokhi UK, Sohn C, Syracuse B, Giannopoulou EG et all. Tumor Necrosis Factor dynamically regulates the mRNA stabilome in rheumatoid arthritisfibro blast-like synoviocytes. PLoS One. 2017;12(7):e0179762. doi: 10.1371/journal.pone.0179762Bustamante M.F., Garcia-Carbonell R., Whisenant K.D., Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. // Arthritis Res Ther. – 2017. – V. 19(1). – P. 110. doi: 10.1186/s13075-017-1303-3Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi: 10.1186/s13075-017-1303-3Tanaka T., Narazaki M., Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. // FEBS Lett. – 2011. – V.585(23). – P.3699-709. doi: 10.1016/j.febslet.2011.03.023Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585(23):3699-709. doi: 10.1016/j.febslet.2011.03.023Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. // Ann Rheum Dis. – 2010. – V. 69(1). – P. 88-96. doi: 10.1136/ard.2008.105197Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ et all. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96. doi: 10.1136/ard.2008.105197Burmester G.R., Rigby W.F., van Vollenhoven R.F., Kay J., Rubbert-Roth A., Kelman A. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. // Ann Rheum Dis. – 2016. – V. 75(6). – P. 1081-91. doi: 10.1136/annrheumdis-2015-207628Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et all. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628Yamamoto K., Goto H., Hirao K., Nakajima A., Origasa H., Tanaka K. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. // J Rheumatol. – 2015. – V. 42(8). – P. 1368-75. doi: 10.3899/jrheum.141210Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K et all. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J Rheumatol. 2015;42(8):1368-75. doi: 10.3899/jrheum.141210Schioppo T., Ingegnoli F. Current perspective on rituximab in rheumatic diseases. // Drug Des Devel Ther. – 2017. - V.11. – P. 2891-2904. doi: 10.2147/DDDT.S139248Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther.2017;11:2891-2904. doi: 10.2147/DDDT.S139248Tak P.P., Rigby W., Rubbert-Roth A., Peterfy C., van Vollenhoven R.F., Stohl W. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. // Ann Rheum Dis. – 2012. – V. 71(3). – P. 351-7. doi: 10.1136/annrheumdis-2011-200170Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W et all. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Tarp U., van Riel P.L. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and lefl unomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. // Ann Rheum Dis.– 2012. – V. 71(3). – P. 374-7. doi: 10.1136/annrheumdis-2011-200003Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL et all. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and lefl unomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. // Arthritis Rheum. – 2006. – V.54(3). – P.711-5.Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT et all. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-5Hayashi S., Suzuki K., Yoshimoto K., Takeshita M., Kurasawa T., Yamaoka K. Early Prognostic Factors Associated with the Efficacy of Infl iximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. // Rheumatol Ther. – 2016. V. 3(1). – P. 155-166.Hayashi S, Suzuki K, Yoshimoto K, Takeshita M, Kurasawa T, Yamaoka K et all. Early Prognostic Factors Associated with the Effi cacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther. 2016;3(1):155-166Atteritano M., Mazzaferro S., Mantuano S., Bagnato G.L., Bagnato G.F. Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis. // Cytotechnology.– 2016. – V. 68(2). – P. 313-8. doi: 10.1007/s10616-014-9782-4Atteritano M, Mazzaferro S, Mantuano S, Bagnato GL, Bagnato G.F. Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis. Cytotechnology. 2016;68(2):313-8. doi: 10.1007/s10616-014-9782-4Th orne C., Bensen W.G., Choquette D., Chow A., Khraishi M., Atkins C.J. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. // Arthritis Care Res (Hoboken). – 2014. – V. 66(8). – P. 1142-51. doi: 10.1002/acr.22290Th orne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ et all. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken).2014;66(8):1142-51. doi: 10.1002/acr.22290Scott L.J. Etanercept: a review of its use in autoimmune inflammatory diseases. // Drugs. – 2014. – V. 74(12). – P. 1379-410. doi: 10.1007/s40265-014-0258-9Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74(12):1379-410. doi: 10.1007/s40265-014-0258-9Bessette L., Khraishi M., Kivitz A.J., Kaliyaperumal A., Grantab R., Poulin-Costello M. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid ArthritisWho Failed Adalimumab Treatment. // Rheumatol Ther. – 2017. – V. 4(2). – P. 391-404. doi: 10.1007/s40744-017-0079-xBessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M et all. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatol Ther. 2017;4(2):391-404. doi: 10.1007/s40744-017-0079-xHobbs K., Deodhar A., Wang B., Bitman B., Nussbaum J., Chung J. Randomized, double-blind, placebo-controlled study to evaluate the effi cacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. // Springerplus. - 2015. - V. 4. – P. 113. doi: 10.1186/s40064-015-0895-9Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J et all. Randomized, double-blind, placebo-controlled study to evaluate the effi cacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus. 2015;4:113. doi: 10.1186/s40064-015-0895-9

The authors declare that there are no conflicts of interest present.